TRUSCREEN GROUP LIMITED — Share Issue/Capital Change 2026

May 24, 2026

truscreen®
a world without cervical cancer

NZX/ASX Announcement

25 May 2026

TruScreen Completes Oversubscribed Placement

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU or Company) is pleased to advise that further to the announcement of 21 May 2026 “TruScreen announces the opening of a NZ$2.9m capital raise”, the Company has received firm commitments from both new and existing investors for an initial placement to institutional and other select investors (“Placement”) of approximately 130 million shares at NZ$0.014/A$0.012 per share to raise approximately NZ$1.82m / A$1.52m before costs.

The Placement was oversubscribed by approximately NZ$820,000. Given that the demand in the Placement was higher than the Company's available placement capacity, the Company has agreed with Placement participants to implement a partial deferred settlement for the Placement as follows:

1. Approximately 110 million shares will be issued under the Company’s existing 15% placement capacity in a tranche 1 issue on 1 June 2026.
2. Approximately 20 million shares will be issued in tranche 2, subject to receiving an NZX waiver to permit the later settlement time and shareholder approval at a meeting to be held on or around 7 July 2026.
3. The Company will issue one free attaching option, for each two (2) new shares issued under the Placement (including shares issued under both tranche 1 and tranche 2), with an exercise price NZ$0.014 /A$0.012 and an expiry date two years from the date of issue, subject to shareholder approval at the shareholder meeting to be held on or around 7 July 2026.

The placement was successfully managed by joint lead managers, S P Corporate Advisory Pty Limited and Erity Capital Pty Limited.

The renounceable rights issue (see Rights Issue Offer Document lodged with NZX/ASX on 21 May 2026), will open on 29 May 2026 providing eligible shareholders on the record date of 28 May 2026, the opportunity to take up their entitlement of one (1) share for every five (5) held at a price of NZ$0.013 /A$0.011. Documents for the Renounceable Rights Issue will be mailed to shareholders on 29 May 2026.

Tony Ho Chairman commented, “we are pleased with the strong support that we have received for this placement. In addition to the growth of our distributor business, conversion of just one of the screening programme submissions under UNITAID’s Global Cervical Cancer Elimination Call could be transformational for the Company.”

truscreen
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
C E
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
QM PROMOTION

---

truscreen®
a world without cervical cancer

In the event shareholders do not receive application forms for the Renounceable Rights Offer please contact the share registry MUFG Corporate Markets:

applications.nz@cm.mpms.mufg.com (Please use “TruScreen Rights Offer”) as the subject of the email, or Telephone +64 9 375 5998 or contact the Company Secretary, contact details below.

This announcement has been approved by the Board.

Ends

Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

truscreen®
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00

---

truscreen®
a world without cervical cancer
^{}[]

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”.

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.

truscreen
a world without cervical cancer
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 13485
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00
1000000000000000000000000000000000000000000000

---

truscreen®
a world without cervical cancer
^{}[]

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

^{}[]
truscreen®
a world without cervical cancer
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00